Author(s): van Dalen EC, van der Pal HJ, Bakker PJ, Caron HN, Kremer LC, van Dalen EC, van der Pal HJ, Bakker PJ, Caron HN, Kremer LC
Abstract Share this page
Abstract Mitoxantrone is believed to maintain anthracycline antitumour activity but be associated with a reduced cardiotoxicity. The aim of this study was to evaluate the evidence for the cumulative incidence of and risk factors for mitoxantrone-induced cardiotoxicity (M-CT) in children treated for childhood cancers. After an extensive literature search, 17 studies were included. The cumulative incidence varied between 0 and 6.7\% in the 16 studies evaluating symptomatic M-CT and between 0 and 80\% in the 11 studies evaluating asymptomatic M-CT. Risk factors for developing M-CT remain unclear. All studies had serious methodological limitations. In conclusion, children treated with mitoxantrone are at risk of developing M-CT, but due to the low quality of the current evidence, the exact cumulative incidence and risk factors for M-CT remain unclear. It is too early to conclude that in children mitoxantrone is less cardiotoxic than anthracyclines. More well-designed studies are needed to reliably evaluate the incidence of M-CT and its associated risk factors.
This article was published in Eur J Cancer
and referenced in Cardiovascular Pharmacology: Open Access